Recently, Genalive, a joint venture between BGI Almanahil Health for Medical Services (a wholly owned subsidiary of BGI Genomics) and Tibbiyah Holding (a wholly owned subsidiary of Saudi Al Faisaliah Group), opened its independent clinical laboratory.

Breast Cancer Canada said on Thursday that it has launched a new grant program in collaboration with AstraZeneca Canada and Illumina.

Eli Lilly and Verve Therapeutics on Thursday said they have entered into an exclusive research collaboration to advance a preclinical gene-editing therapy for atherosclerotic cardiovascular disease (ASCVD) into the clinical stage.

MGI Tech, a Shenzhen, China-based firm focused on the development and distribution of sequencing instruments and reagents, on Wednesday announced that it has signed a licensing agreement with Xpress Genomics.

Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem™ Business.

Asep Medical has entered a definitive agreement with Seaspring for sepsis diagnosis technology Sepset.

MGI Tech Co., Ltd. (referred to as MGI) announced that it has entered into a comprehensive cooperation with AddLife AB, one of Europe's largest clinical testing and laboratory equipment channel providers based in Stockholm, Sweden, to accelerate the expansion of MGI's sequencing instrument and laboratory automation equipment in the Nordic region.

T2 Biosystems said on Friday that it is collaborating with Vanderbilt University Medical Center to implement and evaluate the firm's T2Bacteria Panel in clinical settings.

South Korean liquid biopsy firm IMBdx said Thursday that it is expanding an ongoing collaboration with AstraZeneca under a project called PROSPER 2.0, which aims to improve access to targeted therapies for individuals with metastatic prostate cancer in markets outside the US.

Life sciences proteomics firm Seer on Wednesday announced an expanded collaboration with Thermo Fisher Scientific.